Private equity firm Veritas to buy Cotiviti in $4.9 billion deal: Reuters


Private equity firm Veritas Capital will buy Cotiviti Holdings Inc (COTV.N) in a deal valued at $4.9 billion, the U.S. healthcare analytics company said on Tuesday.

Cotiviti shareholders will receive $44.75 per share in cash, representing a premium of 12.2 percent to the stock’s closing price on Monday. Veritas will assume Cotiviti’s outstanding debt.

Atlanta-based Cotiviti, which provides payment accuracy and analytics services to health insurers and other healthcare companies, will combine with Veritas-controlled Verscend Technologies Inc.

Cotiviti shares jumped 10.3 percent to $44 in premarket trading.

Cotiviti shareholder Advent International – whose shares represent some 44 percent of the healthcare analytics firm’s voting power – will vote in favor of the deal.

Goldman Sachs and William Blair were Cotiviti’s financial advisers. Latham & Watkins LLP provided legal counsel.

Skadden, Arps, Slate, Meagher & Flom LLP was Veritas’ legal adviser.

PE Hub Healthcare Wire delivers private equity and M&A healthcare deal activity, fundraising news, people moves, regulatory updates and much more every Thursday. Subscribe now! It’s FREE.

Do you want exclusive news and analysis about private equity deals, fundraising, top-quartile managers and more? Get your FREE trial to Buyouts! Or subscribe now!

PE Hub Healthcare Wire delivers private equity and M&A healthcare deal activity, fundraising news, people moves, regulatory updates and much more every Thursday. Subscribe now! It’s FREE.